Clinical significance of serum levels of immune-associated molecules, uric acid and soluble MHC class I chain-related molecules A and B, as diagnostic tumor markers for pancreatic ductal adenocarcinoma

Cancer Science

Volumn 102, Issue 9, 2011, Pages 1673-1679

  Chung, Hye Won ^a,c   Lim, Jong Baeck ^b  

^a Soonchunhyang University   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1 MOLECULE A; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1 MOLECULE B; TUMOR ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG; URIC ACID;

ADULT; ARTICLE; CARCINOGENESIS; CHRONIC PANCREATITIS; DISTANT METASTASIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; T LYMPHOCYTE;

ALGORITHMS; CA-19-9 ANTIGEN; CARCINOMA, PANCREATIC DUCTAL; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; URIC ACID;

EID: 80051803606     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.01989.x     Document Type: Article

References (32)

1. Lillemoe KD, Yeo CJ, Cameron JL. Pancreatic cancer: state of- the-art care. CA Cancer J Clin 2000; 50: 241-68.
2. Mulcahy MF, Wahl AO, Small W Jr. The current status of combined radiotherapy and chemotherapy for locally advanced or resected pancreas cancer. J Natl Compr Canc Netw 2005; 3: 637-42.
3. Camacho D, Reichenbach D, Duerr GD, Venema TL, Sweeney JF, Fisher WE. Value of laparoscopy in the staging of pancreatic cancer. J Ophthalmol 2005; 6: 552-61.
4. Locker GY, Hamilton S, Harris J et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006; 24: 5313-27.
5. Chang CY, Huang SP, Chiu HM, Lee YC, Chen MF, Lin JT. Low efficacy of serum levels of CA 19-9 in prediction of malignant diseases in asymptomatic population in Taiwan. Hepatogastroenterology 2006; 53: 1-4.
6. Clavé P, Boadas J, González-Carro P et al. Accuracy of imaging techniques and tumor markers in the diagnosis of pancreatic cancer. Gastroenterol Hepatol 1999; 22: 335-41.
7. Akdoǧan M, Saşmaz N, Kayhan B, Biyikoǧlu I, Dişibeyaz S, Sahin B. Extraordinarily elevated CA19-9 in benign conditions: a case report and review of the literature. Tumori 2001; 87: 337-9.
8. Kayhan B, Kayhan B, Akdogan M. Can IL-2R alpha be a valuable marker along with CA 19-9 in the diagnosis of chronic pancreatitis and pancreatic cancer. Int J Biol Markers 2004; 19: 196-02.
9. Heinig M, Johnson RJ. Role of uric acid in hypertension, renal disease, and metabolic syndrome. Cleve Clin J Med 2006; 73: 1059-64.
10. Dehghan A, Van Hoek M, Sijbrands EJ, Hofman A, Witteman JC. High serum uric acid as a novel risk factor for type 2 diabetes. Diabetes Care 2008; 31: 361-2.
11. Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003; 425: 516-21.
12. Ullrich E, Ménard C, Flament C et al. Dendritic cells and innate defense against tumor cells. Cytokine Growth Factor Rev 2008; 19: 79-92.
13. Bauer S, Groh V, Wu J et al. Activation of NK cells and T cells by NKG2D, a receptor for stress inducible MICA. Science 1999; 285: 727-9.
14. Salih HR, Rammensee HG, Steinle A. Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J Immunol 2002; 169: 4098-102.
15. Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002; 419: 734-8.
16. Holdenrieder S, Stieber P, Peterfi A, Nagel D, Steinle A, Salih HR. Soluble MICA in malignant diseases. Int J Cancer 2006; 118: 684-7.
17. Märten A, von Lilienfeld-Toal M, Büchler MW, Schmidt J. Soluble MIC is elevated in the serum of patients with pancreatic carcinoma diminishing gammadelta T cell cytotoxicity. Int J Cancer 2006; 119: 2359-65.
18. Holdenrieder S, Stieber P, Peterfi A, Nagel D, Steinle A, Salih HR. Soluble MICB in malignant diseases: analysis of diagnostic significance and correlation with soluble MICA. Cancer Immunol Immunother 2006; 55: 1584-9.
19. Greene FL, Page DL, Fleming ID et al., eds. AJCC Cancer Staging Manual. Ann Arbor, MI: Springer, 2002.
20. McIntosh MW, Pepe MS. Combining several screening tests: optimality of the risk score. Biometrics 2002; 58: 657-64.
21. Ames BN, Cathcart R, Schweirs E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA 1981; 78: 6858-62.
22. Strasak AM, Rapp K, Hilbe W et al. The role of serum uric acid as an antioxidant protecting against cancer: prospective study in more than 28000 older Austrian women. Ann Oncol 2007; 18: 1893-7.
23. Lickl E, Alth G, Ebermann R, Beck RH, Tuma K. Serum urate level and cancer. Med Hypotheses 1989; 28: 193-5.
24. Hiatt RA, Fireman BH. Serum uric acid unrelated to cancer incidence in humans. Cancer Res 1988; 48: 2916-18.
25. Yossepowitch O, Pinchuk I, Gur U, Neumann A, Lichtenberg D, Baniel J. Advanced but not localized prostate cancer is associated with increased oxidative stress. J Urol 2007; 178: 1238-43.
26. Ultmann JE. Hyperuricemia in disseminated neoplastic disease other than lypmphomas and leukemias. Cancer 1962; 15: 122-9.
27. Thornton AM, Donovan EE, Piccirillo CA, Shevach EM. Cutting edge: IL-2 is critically required for the in vitro activation of CD4+CD25+ T cell suppressor function. J Immunol 2004; 172: 6519-23.
28. Lange F, Rateitschak K, Fitzner B, Pöhland R, Wolkenhauer O, Jaster R. Studies on mechanisms of interferon-gamma action in pancreatic cancer using a data-driven and model-based approach. Mol Cancer 2011; 10: 13-25.
29. Pestka S, Krause CD, Sarkar D, Walter MR, Shi Y, Fisher PB. Interleukin-10 and related cytokines and receptors. Annu Rev Immunol 2004; 22: 929-79.
30. Nachmani D, Stern-Ginossar N, Sarid R, Mandelboim O. Diverse herpesvirus microRNAs target the stress-induced immune ligand MICB to escape recognition by natural killer cells. Cell Host Microbe 2009; 5: 376-85.
31. Spies T. Regulation of NKG2D ligands: a purposeful but delicate affair. Nat Immunol 2008; 9: 1013-5.
32. Salih HR, Goehlsdorf D, Steinle A. Release of MICB molecules by tumor cells: mechanism and soluble MICB in sera of cancer patients. Hum Immunol 2006; 67: 188-95.